Can You Drink Alcohol on Semaglutide (Wegovy / Ozempic)?

What the labels say about alcohol

Neither the Wegovy nor the Ozempic drug interaction section lists alcohol, and neither sets a drinking limit [1][2]. Both sections cover two things: insulin or an insulin secretagogue such as a sulfonylurea, and oral medicines in general, because semaglutide delays gastric emptying and may change their absorption [1][2]. The Rybelsus and Ozempic tablets label covers the same categories and also does not list alcohol [3].

We found no published study that tested alcohol with semaglutide.

Tablet timing and other drinks

Wegovy tablets, Rybelsus and Ozempic tablets are taken once daily on an empty stomach in the morning with up to 4 ounces of water, and no other liquid [1][3]. The tablet is swallowed whole and not split, crushed, chewed or dissolved [1][3]. After the dose, at least 30 minutes must pass before food, any beverage other than water, or other oral medicines [1][3].

The tablet labels apply this wait to any beverage other than water. The injection labels carry no such timing rule: Wegovy and Ozempic are injected once weekly at any time of day, with or without meals [1][2].

Stomach side effects

Gastrointestinal reactions are the most common problem on semaglutide and are worst during dose escalation [1]. In the Wegovy 2.4 mg weight-management trials, nausea occurred in 44% vs 16% on placebo, diarrhea in 30% vs 16%, vomiting in 24% vs 6% and constipation in 24% vs 11%; any GI reaction occurred in 73% vs 47%, and 6.8% vs 3.2% stopped treatment because of adverse reactions [1]. For Ozempic in type 2 diabetes, any GI reaction occurred in 36.4% on 1 mg and 32.7% on 0.5 mg vs 15.3% on placebo [2].

Low blood sugar with insulin or a sulfonylurea

Semaglutide lowers blood glucose and can cause hypoglycemia [1]. The risk is higher when it is combined with insulin or an insulin secretagogue such as a sulfonylurea, and the labels advise considering a lower dose of those drugs when semaglutide is started [1][2].

In a Wegovy trial in adults with type 2 diabetes and a BMI of 27 or higher, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg vs 2.5% on placebo, and the Wegovy label says risk was higher with a sulfonylurea [1]. That figure comes from the Wegovy trial; the Ozempic label gives its own hypoglycemia warning for insulin and secretagogues without those rates [2].

Pancreatitis

The Wegovy label warns that acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Wegovy, and describes the symptoms as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting; it says to discontinue Wegovy and begin appropriate management if pancreatitis is suspected [1]. The Ozempic label carries the same warning [2].